Created at	Source	Raw Value	Validated value
Nov. 26, 2021, 10:30 p.m.	oms	The co-primary efficacy outcome for this trial is a <br/ >composite of invasive ventilation or death at 30 days after randomization. <br/ >The co-primary safety outcome for this trial is any incident cases of hypopnea that results from a failure of the device at 30 days after randomizationTimepoint: 30 days after randomization	The co-primary efficacy outcome for this trial is a <br/ >composite of invasive ventilation or death at 30 days after randomization. <br/ >The co-primary safety outcome for this trial is any incident cases of hypopnea that results from a failure of the device at 30 days after randomizationTimepoint: 30 days after randomization
Nov. 13, 2021, 5:33 p.m.	oms	N/A	N/A
Dec. 5, 2020, 12:45 a.m.	oms	The co-primary efficacy outcome for this trial is a <br/ >composite of invasive ventilation or death at 30 days after randomization. <br/ >The co-primary safety outcome for this trial is any incident cases of hypopnea that results from a failure of the device at 30 days after randomizationTimepoint: 30 days after randomization	The co-primary efficacy outcome for this trial is a <br/ >composite of invasive ventilation or death at 30 days after randomization. <br/ >The co-primary safety outcome for this trial is any incident cases of hypopnea that results from a failure of the device at 30 days after randomizationTimepoint: 30 days after randomization